Vaccine Near-Halves Return Risk; Moderna Stock Plunges — SkimNews
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- BBC described the first personalised cancer vaccine as cutting the risk of disease returning in a major trial, while The Washington Post said a vaccine for the deadliest skin cancer cut risk by almost half.
- Moderna's stock reaction was sharply negative as investors digested melanoma-vaccine trial data: Yahoo Finance described losses as being trimmed, while another headline said the stock plummeted.
Why it matters: For participants in the melanoma trial, the result was a reduction of almost half in recurrence risk. For Moderna investors, the same data were paired with a stock plunge as investors digested the trial, showing that the clinically favorable headline did not produce an immediate positive market response.
Ask SkimNews
